Absci Management

Management criteria checks 2/4

Absci's CEO is Sean McClain, appointed in Aug 2011, has a tenure of 12.75 years. total yearly compensation is $3.10M, comprised of 20% salary and 80% bonuses, including company stock and options. directly owns 7.64% of the company’s shares, worth $40.95M. The average tenure of the management team and the board of directors is 1.5 years and 1.3 years respectively.

Key information

Sean McClain

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage	20.0%
CEO tenure	12.8yrs
CEO ownership	7.6%
Management average tenure	1.5yrs
Board average tenure	1.3yrs

Recent management updates

Recent updates

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

Jan 10

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

Jul 22

CEO Compensation Analysis

How has Sean McClain's remuneration changed compared to Absci's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$3m	US$620k	-US$111m
Sep 30 2023	n/a	n/a	-US$106m
Jun 30 2023	n/a	n/a	-US$112m
Mar 31 2023	n/a	n/a	-US$99m
Dec 31 2022	US$4m	US$600k	-US$105m
Sep 30 2022	n/a	n/a	-US$111m
Jun 30 2022	n/a	n/a	-US$107m
Mar 31 2022	n/a	n/a	-US$121m
Dec 31 2021	US$4m	US$505k	-US$103m
Sep 30 2021	n/a	n/a	-US$84m
Jun 30 2021	n/a	n/a	-US$73m
Mar 31 2021	n/a	n/a	-US$48m
Dec 31 2020	US$1m	US$260k	-US$49m

Compensation vs Market: Sean's total compensation ($USD3.10M) is about average for companies of similar size in the US market ($USD2.41M).

Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.

CEO

Sean McClain (33 yo)

12.8yrs

Tenure

US$3,097,371

Compensation

Mr. Sean Mcclain is the Founder of Absci Corporation (formerly known as AbSci, LLC) and serves as its Chief Executive Officer since August 2011 and Director since its formation in October 2020. Mr. Mcclain...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sean McClain	Founder	12.8yrs	US$3.10m	7.64% $ 40.9m
Zachariah Jonasson	Chief Business Officer & CFO	less than a year	US$2.20m	0.0080% $ 42.7k
Andreas Busch	Chief Innovation Officer & Member of Scientific Advisory Board	1.6yrs	US$2.15m	no data
Todd Bedrick	Senior VP & Chief Accounting Officer	1.8yrs	no data	0.0027% $ 14.2k
Alexander Khan	VP of Finance & Head of Investor Relations	1.2yrs	no data	no data
Karin Wierinck	Chief People Officer	1.3yrs	no data	no data
Melissa Patterson	Chief of Staff	2.2yrs	no data	no data
Jens Plassmeier	Senior VP of Biologics Discovery Technology	2.3yrs	no data	no data
Wen Sha	Chief of Staff	2.3yrs	no data	no data
Christine Lemke	Senior Vice President of Portfolio & Growth Strategy	1.3yrs	no data	no data
Christian Stegmann	Senior Vice President of Drug Creation	1.3yrs	no data	no data
Amaro Taylor-Weiner	Chief AI Officer	less than a year	no data	no data

1.5yrs

Average Tenure

50yo

Average Age

Experienced Management: ABSI's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Sean McClain	Founder	3.6yrs	US$3.10m	7.64% $ 40.9m
Andreas Busch	Chief Innovation Officer & Member of Scientific Advisory Board	less than a year	US$2.15m	no data
Karen McGinnis	Lead Independent Director	3.8yrs	US$169.46k	0.013% $ 71.1k
François van Houten	Independent Director	less than a year	US$171.92k	no data
Daniel Rabinovitsj	Independent Director	1.5yrs	US$96.37k	0% $ 0
Timothy Lu	Member of Scientific Advisory Board	1.3yrs	no data	no data
Menelas Nicolas Pangalos	Independent Director & Member of Scientific Advisory Board	less than a year	no data	no data
Joseph Sirosh	Independent Director	2.3yrs	US$101.59k	0% $ 0
Amrit Nagpal	Independent Director	3.6yrs	US$108.87k	no data
Victor Greiff	Member of Scientific Advisory Board	1.3yrs	no data	no data
Hubert Truebel	Member of Scientific Advisory Board	1.3yrs	no data	no data

1.3yrs

Average Tenure

56yo

Average Age

Experienced Board: ABSI's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Absci Management

Management criteria checks 2/4

Key information

Recent management updates

Absci Corporation Appoints Menelas Pangalos as Class II Director and Member of Compensation Committee of the Board, Effective January 1, 2024

Absci Corporation Announces Resignation of Sarah Korman as Chief Legal Officer and Interim Chief Business Officer, Effective as of September 15, 2023

Absci Corporation Appoints Zach Jonasson as Chief Business Officer, Effective from August 31, 2023

Absci Corporation Appoints Frans Van Houten to Its Board of Directors

Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation

High number of new and inexperienced directors

Recent updates

Absci Corporation to Report Q1, 2024 Results on May 14, 2024

Consensus revenue estimates fall by 20%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates decrease by 13%

New minor risk - Shareholder dilution

Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.

Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.

Absci: Differentiated Antibody Discovery Play

Absci Initiates IND-Enabling Studies for Abs-101, A Potential Best-In-Class Anti-Tl1a Antibody De Novo Designed and Optimized Using Generative Ai

Absci Corporation to Present Preclinical Data for ABS-101, A Potential Best-In-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference

Absci Corporation Appoints Menelas Pangalos as Class II Director and Member of Compensation Committee of the Board, Effective January 1, 2024

Price target decreased by 14% to US$5.76

Consensus revenue estimates decrease by 42%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 15% to US$5.50

Consensus EPS estimates fall by 21%, revenue upgraded

Absci Corporation Announces Resignation of Sarah Korman as Chief Legal Officer and Interim Chief Business Officer, Effective as of September 15, 2023

Absci Corporation Appoints Zach Jonasson as Chief Business Officer, Effective from August 31, 2023

Absci Corporation Reports Impairment Results for the Second Quarter Ended June 30, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Absci Corporation and California Institute of Technology Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

New major risk - Share price stability

Absci Corporation Appoints Frans Van Houten to Its Board of Directors

Price target decreased by 10% to US$7.73

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Casdin Capital Engages in Discussions with Absci Corporation

Price target decreased by 28% to US$8.60

Consensus revenue estimates decrease by 23%, EPS upgraded

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Casdin Capital Engages in Discussions with Absci Corporation

Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation

Absci Corporation Announces Ability to Create and Validate de novo Antibodies in Silico with Use of Zero-Shot Generative AI

Consensus forecasts updated

Price target decreased to US$12.10

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Absci Corporation Appoints Dan Rabinovitsj as Newest Member of its Board of Directors

Chief Financial Officer exercised options to buy US$155k worth of stock.

Absci Corporation Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer

Absci Corporation Announces End of Nikhil Goel as Chief Strategy Officer

Price target decreased to US$13.10

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M

Eli Casdin Resigns from Board of Directors of Absci Corporation

Absci teams up to help develop antibody drugs for cancer

Absci Corporation(NasdaqGS:ABSI) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus EPS estimates fall by 29%

Consensus revenue estimates fall by 17%

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$0.33 loss per share

Absci, CORP has completed an IPO in the amount of $200 million.

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age